Therefore, high levels of ENT1 predict a good response of pancreatic cancer to gemcitabine treatment, whereas the loss of ENT1 leads to chemical drug resistance [63,64]. The gene discussed is SLC29A1; the disease is familial pancreatic carcinoma.